Kymera Therapeutics, Inc. (KYMR)
NASDAQ:KYMR
Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$87.71
-$0.34(-0.84%)
At close: 4:00 PM EST
$87.71
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$36.65 - $103.00
Previous CloseN/A
Volume48.51K
Average Volume (3M)495.85K
Market Cap
$5.86B
Enterprise Value$6.63B
Total Cash (Recent Filing)$650.93M
Total Debt (Recent Filing)$80.47M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Jul 31, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,257,590
10 Day Avg. Volume494,935
30 Day Avg. Volume495,852
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue128.90
Enterprise Value/Gross Profit128.90
Enterprise Value/Ebitda-21.68
Forecast
1Y Price Target
$119.13Price Target Upside35.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$80.10M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Sizable EquityA very low debt-to-equity ratio and substantial equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D investment, and gives the company time to advance programs before needing to service meaningful debt.
Accelerating Top-line MomentumSustained revenue growth of ~31% TTM signals improving commercialization of collaboration and licensing activities. Consistent top-line expansion strengthens funding options, validates partner interest in the platform, and helps partially offset R&D spend over the medium term.
Partnership-driven Funding And Pipeline ValidationA business model anchored in collaborations and licensing spreads development cost and provides non-dilutive or milestone-linked funding. Strategic deals (e.g., Gilead option exercise) also signal external validation of the protein degrader platform and enhance resource access for pivotal programs.
Bears Say
Heavy Cash BurnConsistent, large negative operating and free cash flow indicates the company is consuming substantial capital to advance multiple clinical programs. Over the medium term this necessitates continued external funding, which can constrain strategic flexibility and increase reliance on partners or financings.
Large Recurring Net LossesPersistent, sizable net losses and deeply negative margins reflect that operating costs far outpace revenue. Until commercial products or consistent milestone income emerge, profitability is unlikely, pressuring returns and limiting the company's ability to self-fund growth long-term.
Dilution And Reliance On Partnership/milestone FundingWith ongoing losses and high cash burn, the company is likely to rely on equity raises and milestone-based partnership payments. This raises the risk of shareholder dilution and makes long-term financing contingent on execution, trial outcomes, and partner decisions rather than predictable operating cash flow.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $36.65 and its highest was $103.00 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $5.86B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 58 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.171.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.73.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 82,257,590 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -0.54%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.13 (35.82% Upside)
$119.13 (35.82% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 104.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.29%
12-Months-Change
Fundamentals
Return on Equity
-25.02%
Trailing 12-Months
Asset Growth
81.75%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum (notably KT-621 and KT-579), significant balance sheet strength (raised ~ $1B; $1.6B year-end cash) and multiple high-value collaborations, all supporting an ambitious development plan. Headwinds include elevated R&D spend (adjusted cash R&D +16% QoQ), limited current revenue, translational/measurement complexity for IRF5, and multi-year timelines to pivotal readouts and potential approvals. Overall, the positives—compelling early clinical data, IND/Phase I starts, partner validation and a multi-year cash runway—outweigh the noted operational and timing risks.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$119.13
▲(35.82% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
12.36% Insiders
33.25% Mutual Funds
14.41% Other Institutional Investors
26.63% Public Companies and
Individual Investors